Assenagon Asset Management S.A. Has $4.07 Million Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Assenagon Asset Management S.A. grew its position in Bio-Rad Laboratories, Inc. (NYSE:BIOFree Report) by 104.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,605 shares of the medical research company’s stock after purchasing an additional 6,429 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Bio-Rad Laboratories were worth $4,070,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in BIO. Farther Finance Advisors LLC grew its position in Bio-Rad Laboratories by 42.3% during the second quarter. Farther Finance Advisors LLC now owns 101 shares of the medical research company’s stock worth $38,000 after buying an additional 30 shares in the last quarter. ING Groep NV acquired a new stake in Bio-Rad Laboratories during the third quarter worth approximately $44,000. Pacific Center for Financial Services acquired a new stake in Bio-Rad Laboratories during the first quarter worth approximately $49,000. Atlas Capital Advisors LLC acquired a new stake in shares of Bio-Rad Laboratories in the 2nd quarter valued at $50,000. Finally, Dark Forest Capital Management LP boosted its holdings in shares of Bio-Rad Laboratories by 1,160.0% in the 1st quarter. Dark Forest Capital Management LP now owns 126 shares of the medical research company’s stock valued at $60,000 after purchasing an additional 116 shares in the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Wall Street Analyst Weigh In

BIO has been the topic of a number of research analyst reports. Royal Bank of Canada reduced their target price on Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating on the stock in a report on Friday, February 16th. UBS Group raised their target price on Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a “buy” rating in a report on Friday, February 16th. Finally, StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, March 15th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $493.75.

Get Our Latest Analysis on BIO

Bio-Rad Laboratories Stock Down 2.0 %

Shares of BIO opened at $338.98 on Tuesday. Bio-Rad Laboratories, Inc. has a 52 week low of $261.59 and a 52 week high of $494.05. The stock has a market capitalization of $9.67 billion, a price-to-earnings ratio of -15.77 and a beta of 0.87. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.34 and a current ratio of 5.83. The stock has a fifty day moving average of $333.30 and a 200-day moving average of $324.33.

Bio-Rad Laboratories (NYSE:BIOGet Free Report) last announced its quarterly earnings results on Thursday, February 15th. The medical research company reported $3.10 EPS for the quarter, beating analysts’ consensus estimates of $2.93 by $0.17. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The company had revenue of $681.18 million during the quarter, compared to analysts’ expectations of $685.00 million. During the same period in the prior year, the company earned $3.31 EPS. Bio-Rad Laboratories’s revenue was down 6.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.57 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Michael Crowley sold 3,000 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total value of $1,008,000.00. Following the completion of the transaction, the executive vice president now directly owns 6,942 shares in the company, valued at approximately $2,332,512. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 17.06% of the stock is owned by corporate insiders.

About Bio-Rad Laboratories

(Free Report)

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Recommended Stories

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIOFree Report).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.